MicroRNA Blood Test for Early ALS Diagnosis Seen as Feasible in Clinic
The levels of five small RNA molecules, called microRNAs, inside tiny vesicles in the blood of people with amyotrophic…
Articles by Marisa Wexler, MS
Bipolar Disorder Therapy May Slow ALS Progression, Pilot Trial Reports
A treatment known as VPA-Li, a combination of lithium carbonate and valproic acid, may slow disease progression and improve quality…
FDA Committee, in Reversal, Favors AMX0035 Approval for ALS
In a reversal, an advisory committee of the U.S. Food and Drug Administration (FDA) now says that the current evidence…
Antibodies Against Viral Protein Tied to Better Survival Rate in ALS
Higher blood levels of antibodies against the viral protein HERV-K ENV are associated with a better survival rate and improved…
Altered, Toxic SOD1 Protein ‘Shared Feature’ Across ALS Types
Altered forms of the SOD1 protein are found in the spinal cord nerve cells of people with all types of…
Gene Therapy SynCav1 Found to Extend Survival in ALS Mouse Model
Treatment with gene therapy candidate SynCav1 delayed disease onset and extended survival in a mouse model of amyotrophic lateral sclerosis (ALS),…
Approved Medication Terazosin May Be ‘Exciting’ New ALS Treatment
Treatment with terazosin, a medication approved to treat high blood pressure and enlarged prostate, was found to protect motor neurons…
ALS Link With Specific STMN2 Gene Mutation Challenged in Study
A mutation in the STMN2 gene that consists of an excessive repeat of two nucleotides, the building blocks of DNA, is not…
Loss of STMN2 Protein Contributes to ALS Progression, Study Finds
TDP-43 protein abnormalities characteristic of most amyotrophic lateral sclerosis (ALS) cases contribute to the loss of motor neurons mostly…
FDA Reviewing Tofersen for SOD1-ALS; Decision Expected in January
The U.S. Food and Drug Administration (FDA) has agreed to review an application from Biogen for approval of the…